Navigation path

NABATIVI


Novel Approaches to Bacterial Target Identification, Validation and Inhibition
EC contribution
: € 5.506.000
Duration
: 48 months
Starting date
: 1/01/2009
Funding scheme
: Focused research project
Keywords
: Gram negative bacteria, antimicrobial resistance, novel drug targets, lead compounds, antibacterials, Pseudomonas aeruginosa, Burkholderia cenocepacia.
Contract/Grant agreement number
: 223670
Project web-site
: http://www.nabativi.org/

Summary:

Despite the advent of the antibiotic era, infectious diseases retain a prominent position as a major worldwide cause of morbidity and mortality. This problem has worsened with the emergence of multi-antibiotic resistant bacteria and the failure of pharmaceutical company drug discovery programmes to design antibiotics with truly novel modes of action. NABATIVI has put together a unique consortium made of six academic institutions and three highly recognized SMEs with complementary expertise in the fields of molecular pathogenicity and high competitiveness in drug discovery, optimisation and preclinical development. The consortium has been specifically designed to generate new strategies leading to the identification and validation of novel targets for antimicrobials using as model organisms the gram-negatives Pseudomonas aeruginosa and Burkholderia cenocepacia as they cause high morbidity and mortality worldwide. The versatility of these model bacteria will enable the results obtained to be extrapolated to other important bacterial pathogens. The extensive involvement of SMEs in this consortium will enable the selection of lead compounds against the identified targets from their large libraries of natural and synthetic chemicals which, after validation, will establish the basis for the development of new classes of antibacterial drugs. This will result in a reduction in the incidence of diseases caused by these organisms with a direct positive impact on the quality of life and the life expectancy of the higher risk patient populations.

[+] Read More